Analyzing Genenta Science (NASDAQ:GNTA) & ADMA Biologics (NASDAQ:ADMA)

Genenta Science (NASDAQ:GNTA) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Profitability

This table compares Genenta Science and ADMA Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
ADMA Biologics	-1.29%	17.24%	7.38%

Valuation & Earnings

This table compares Genenta Science and ADMA Biologics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$12.60 million	N/A	N/A
ADMA Biologics	$283.18 million	9.71	-$28.24 million	($0.02)	-593.00

Genenta Science has higher earnings, but lower revenue than ADMA Biologics.

Risk & Volatility

Genenta Science has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Insider and Institutional Ownership

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Genenta Science and ADMA Biologics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	0	0	1	0	3.00
ADMA Biologics	0	0	3	1	3.25

Genenta Science currently has a consensus target price of $25.00, indicating a potential upside of 481.40%. ADMA Biologics has a consensus target price of $12.25, indicating a potential upside of 3.29%. Given Genenta Science’s higher possible upside, equities research analysts plainly believe Genenta Science is more favorable than ADMA Biologics.

Summary

ADMA Biologics beats Genenta Science on 7 of the 12 factors compared between the two stocks.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.